Precigen is at the forefront of developing next-generation gene and cell therapies, focusing on precision technology to address critical health challenges in immuno-oncology, autoimmune disorders, and infectious diseases. Their innovative platforms, such as the AdenoVerse and UltraCAR-T, leverage proprietary adenovectors and non-viral gene delivery systems to enhance the efficacy and safety of therapies. The AdenoVerse platform utilizes gorilla adenovectors, which are characterized by a large payload capacity, low seroprevalence, and the ability for repeat administration, allowing for durable immune responses. This platform is designed to deliver vaccine antigens and therapeutic genes efficiently, making it suitable for a range of applications in immunotherapy.

The UltraCAR-T platform represents a significant advancement in CAR-T cell therapy, addressing the limitations of traditional methods by enabling rapid, decentralized manufacturing and reducing costs. Utilizing a non-viral Sleeping Beauty system, UltraCAR-T cells can be engineered to express multiple therapeutic genes, including a proprietary membrane-bound interleukin-15 (mbIL15) that enhances T-cell activation and persistence. This innovative approach not only improves the safety profile of the therapies through integrated kill switch technology but also allows for a streamlined manufacturing process that can produce autologous CAR-T cells within a day. Precigen's commitment to precision immunology positions it as a leader in the development of effective and accessible treatments for complex diseases.

United States

Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept and commercialization.

Cancer

Hematologic Diseases

Immune System Diseases

Infectious Diseases

Pharyngeal Diseases

Urogenital Diseases

Precigen

Recurrent respiratory papillomatosis

PRGN-2012 is an innovative therapeutic vaccine with optimized antigen design that uses Precigen’s gorilla adenovector technology, part of Precigen’s proprietary AdenoVerse platform, to elicit immune responses directed against cells infected with human papillomavirus (HPV) type 6 (HPV 6) or HPV type 11 (HPV 11)

PRGN-2012 AdenoVerse™ (zopapogene imadenovec)

Solid tumor/s

Squamous cancers

HPV infects the squamous cells that line the inner surfaces of certain organs and, consequently, most HPV-related cancers are a type of cancer called squamous cell carcinoma¹

PRGN-2009 OTS AdenoVerse™ +/- Pembrolizumab

Cervical cancer

PRGN-2009 AdenoVerse™ + Pembrolizumab

Ovarian cancer

PRGN-3005 UltraCAR-T is a multigenic autologous CAR-T cell therapy utilizing Precigen’s advanced non-viral gene delivery system to simultaneously express a chimeric antigen receptor optimized to preferentially target the unshed portion of Mucin 16 (MUC16) on tumor cells, membrane-bound interleukin-15 (mbIL15), and a kill switch. Mucin 16 (MUC16) is overexpressed on over 80% of ovarian tumors with limited expression found in healthy tissues
CAR T

PRGN-3005 UltraCAR-T® 

Acute myeloid leukemia

PRGN-3006 UltraCAR-T is a multigenic autologous CAR-T cell therapy utilizing Precigen’s advanced non-viral gene delivery system to simultaneously express a chimeric antigen receptor targeting CD33, membrane-bound interleukin-15 (mbIL15), and a kill switch.CD33 is overexpressed on myeloid leukemia cells and leukemic stem cells.
CAR T

PRGN-3006 UltraCAR-T®

Blood cancer

PRGN-3007 UltraCAR-T is a first-in-class investigational multigenic, autologous CAR-T cell therapy utilizing Precigen's clinically validated advanced non-viral gene delivery system and well-established overnight, decentralized manufacturing process. Precigen has further advanced the UltraCAR-T platform to address the inhibitory tumor microenvironment by incorporating intrinsic checkpoint blockade without the need for complex and costly gene editing techniques. PRGN-3007 is engineered using a single multicistronic transposon plasmid to simultaneously express a chimeric antigen receptor (CAR) targeting ROR1, membrane-bound interleukin–15 (mbIL15), a kill switch, and a novel mechanism for the intrinsic blockade of PD-1 gene expression. The innovative design of PRGN-3007, where the blockade of PD-1 expression is intrinsic and localized to UltraCAR-T cells, is aimed at avoiding systemic toxicity and the high cost of checkpoint inhibitors by eliminating the need for combination treatment.
CAR T

PRGN-3007 UltraCAR-T®

Diabetes

Type 1 diabetes

Delivery of the autoantigen human Proinsulin (hPINS) and human Interleukin-10 (hIL-10) to potentially re-establish long-lasting immunological tolerance to islet-antigens and reverse the autoimmune phenotype

Precigen

Company Details